Wound care is not a glamorous corner of medicine, but it generates steady, recurring revenue – and private equity has noticed. Across the country, independent wound care clinics that once operated quietly under the radar are now fielding acquisition offers, often from PE-backed platforms looking to assemble regional or national networks one practice at a time.
Why Wound Care Is Suddenly Attractive to Investors
The basic economics are hard to ignore. Chronic wounds – diabetic foot ulcers, venous leg ulcers, pressure injuries – affect a large and growing patient population, driven by aging demographics and rising rates of diabetes and obesity. These are not one-time visits. Patients return weekly, sometimes for months. That kind of visit frequency produces a revenue model that looks less like a medical practice and more like a subscription business, which is exactly the kind of cash flow predictability PE firms prize when building a platform.
Reimbursement is another draw. Medicare covers a wide range of wound care services, including hyperbaric oxygen therapy, debridement, and advanced wound dressings. The billing is complex, but the rates are relatively favorable compared to other outpatient specialties. A clinic running at strong capacity can generate margins that justify the acquisition multiples PE is willing to pay, especially when the platform can standardize billing and coding across dozens of locations and capture efficiency gains that a solo operator never could.
The specialty also sits in a structural sweet spot. It is too specialized for general practitioners to handle well, too fragmented to have attracted major health system dominance in most markets, and too clinical to be easily disrupted by telehealth. That combination – specialized, fragmented, defensible – is a near-perfect profile for a rollup strategy. PE platforms have used the same playbook in regional dermatology practices with considerable success, and wound care checks many of the same boxes.
What makes wound care slightly different is the acuity of the patient population. These are often elderly, diabetic, or immunocompromised patients who depend on consistent, high-quality care. The stakes of getting it wrong – a missed infection, a delayed referral, a wound that should have prompted amputation prevention – are real. That clinical complexity does not deter PE interest, but it does mean that operators who cut too aggressively on staffing or supplies tend to see outcomes deteriorate faster than they would in lower-acuity specialties.
How the Acquisition Process Actually Works
Most wound care clinic owners do not go looking for a buyer. The first call typically comes from a broker or a platform’s business development team, framed as a “partnership opportunity” or a conversation about growth capital. The language is deliberately soft. PE-backed acquirers have learned that physicians respond poorly to feeling like they are being purchased, so the pitch emphasizes clinical autonomy, back-office support, and the ability to focus on medicine rather than management. Whether those promises hold post-close is a separate question.
Valuations are calculated as a multiple of EBITDA – earnings before interest, taxes, depreciation, and amortization – and the multiples for wound care practices have been climbing. A well-run clinic with strong documentation, clean billing records, and an experienced clinical staff can command a multiple that would have seemed absurd a decade ago. Sellers who have been approached multiple times report that offers have become more aggressive as competition among platforms increases. When two or three PE-backed groups are bidding on the same clinic, prices go up and due diligence timelines compress.
The deal structure usually involves a cash payment at close, a rollover equity stake in the acquiring platform, and an employment agreement tying the selling physician to the practice for several years. That rollover equity is the piece sellers most often misunderstand. It represents a bet that the platform will grow and eventually sell to a larger buyer – a secondary or tertiary transaction – at an even higher multiple. If the platform performs, the rollover can be worth more than the initial cash. If it does not, or if the market tightens before a second exit, the equity may be worth significantly less than projected.
Due diligence on the buyer’s side focuses heavily on payer mix, documentation quality, and the physician’s role in driving patient volume. A clinic where the founding physician is the primary referral relationship and clinical draw is a riskier acquisition than one with a diversified referral network and a multi-clinician staff. Platforms increasingly look for practices where the operator can step back without the revenue walking out the door. Sellers who are deeply embedded in every clinical and operational decision often find their employment agreements come with more restrictive terms.
Post-acquisition integration is where the reality of the deal becomes clear. Platforms typically move quickly to standardize electronic health records, renegotiate supply contracts, and centralize billing. Some of these changes genuinely benefit the clinic – buying power and professional billing teams are real advantages for small practices. Others are efficiency measures that prioritize throughput. Staff who were accustomed to a slower, more relationship-driven environment sometimes struggle. Turnover in the first twelve to eighteen months after a wound care acquisition is a pattern that shows up consistently enough to be worth asking about before signing.
What Sellers Are Getting Right – and Getting Wrong
The owners who navigate these deals best tend to do two things differently. They get independent legal and financial counsel before the first meeting, not after the letter of intent arrives. And they ask hard questions about the platform’s existing portfolio – patient satisfaction trends, staff retention rates, and what happened to the physicians who sold two years ago. PE-backed acquirers are not uniformly bad operators, but the range of outcomes across platforms is wide, and the information asymmetry between a first-time seller and a firm that has closed dozens of deals is significant. Physicians who treat the process like a clinical consult – gathering data, asking for references, getting a second opinion – tend to end up in better positions.
The harder question is what happens to patients when a wound care clinic changes hands and then changes hands again. A platform that sells to a larger operator, or gets taken private by a bigger fund, may have priorities that shift further from the original clinical mission. Wound care patients are often among the most vulnerable in outpatient medicine, and their continuity of care depends on staff relationships and institutional knowledge that does not always survive multiple transactions. That tension is not unique to wound care – it runs through every specialty undergoing consolidation – but it is particularly sharp here, where the margin between a healed wound and an amputation can come down to whether the same nurse practitioner showed up for the third consecutive weekly visit.
